Melatonin therapy for REM sleep behavior disorder: A critical review of evidence

Sleep Medicine

Volumn 16, Issue 1, 2015, Pages 19-26

  McGrane, Ian R ^a   Leung, Jonathan G ^b   St Louis, Erik K ^b   Boeve, Bradley F ^b  

^a Shodair Children's Hospital   (United States)

^b Mayo Clinic College of Medicine   (United States)

Author keywords

Calmodulin; Drug therapy; Melatonin; Parasomnia; REM sleep behavior disorder

Indexed keywords

CLONAZEPAM; MELATONIN; PLACEBO; CENTRAL DEPRESSANT AGENT;

ADVERSE OUTCOME; CIRCADIAN RHYTHM; DELUSION; DIZZINESS; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EVENING DOSAGE; HALLUCINATION; HEADACHE; HUMAN; LATENT PERIOD; MUSCLE TONE; OUTCOME ASSESSMENT; PARASOMNIA; POLYPHARMACY; POSITIVE END EXPIRATORY PRESSURE; REM SLEEP; REMISSION; REVIEW; SCORING SYSTEM; SLEEP EFFICIENCY; SLEEP PARAMETERS; SLEEP TIME; SLEEP WAKING CYCLE; UNSTEADINESS; PATHOPHYSIOLOGY; REM SLEEP BEHAVIOR DISORDER; TREATMENT OUTCOME;

CENTRAL NERVOUS SYSTEM DEPRESSANTS; HUMANS; MELATONIN; REM SLEEP BEHAVIOR DISORDER; TREATMENT OUTCOME;

EID: 84921325608     PISSN: 13899457     EISSN: 18785506     Source Type: Journal    
DOI: 10.1016/j.sleep.2014.09.011     Document Type: Review

References (63)

1. Tinuper P., Bisulli F., Provini F. The parasomnias: mechanisms and treatment. Epilepsia 2012, 53(Suppl. 7):12-19. 10.1111/j.1528-1167.2012.03710.x.
2. Boeve B.F. REM sleep behavior disorder: updated review of the core features, the REM sleep behavior disorder-neurodegenerative disease association, evolving concepts, controversies, and future directions. Ann N Y Acad Sci 2010, 1184:15-54. 10.1111/j.1749-6632.2009.05115.x.
3. Luppi P.H., Clément O., Valencia Garcia S., Brischoux F., Fort P. New aspects in the pathophysiology of rapid eye movement sleep behavior disorder: the potential role of glutamate, gamma-aminobutyric acid, and glycine. Sleep Med 2013, 14(8):714-718.
4. Fantini M.L., Puligheddu M., Cicolin A. Sleep and violence. Curr Treat Options Neurol 2012, 14(5):438-450. 10.1007/s11940-012-0187-4.
5. Olson E.J., Boeve B.F., Silber M.H. Rapid eye movement sleep behaviour disorder: demographic, clinical and laboratory findings in 93 cases. Brain 2000, 123(Pt 2):331-339.
6. McCarter S.J., St Louis E.K., Boswell C.L., et al. Injury in REM sleep behavior disorder. Sleep Med 2014, 10.1016/j.sleep.2014.06.002.
7. Schenck C., Hurwitz T., Mahowald M. REM sleep behavior disorder: an update on a series of 96 patients and a review of the world literature. J Sleep Res 1993, 2:224-231.
8. Schenck C.H., Milner D.M., Hurwitz T.D., Bundlie S.R., Mahowald M.W. A polysomnographic and clinical report on sleep-related injury in 100 adult patients. Am J Psychiatry 1989, 146(9):1166-1173.
9. Gross P.T. REM behavior disorder causing bilateral subdural hematomas [abstract]. Sleep Res 1992, 21:204.
10. Dyken M.E., Lin-Dyken D.C., Seaba P., Yamada T. Violent sleep-related behavior leading to subdural hemorrhage. Arch Neurol 1995, 52(3):318-321.
11. McCarter S.J., St Louis E.K., Boeve B.F. REM sleep behavior disorder and REM sleep without atonia as an early manifestation of degenerative neurological disease. Curr Neurol Neurosci Rep 2012, 12:182-192.
12. Postuma R.B., Gagnon J.F., Vendette M., et al. Quantifying the risk of neurodegenerative disease in idiopathic REM sleep behavior disorder. Neurology 2009, 72:1296-1301.
13. Boeve B.F., Silber M.H., Ferman T.J., et al. Clinicopathologic correlations in 172 cases of rapid eye movement sleep behavior disorder with or without a coexisting neurologic disorder. Sleep Med 2013, 14:754-762.
14. Schenck C.H., Boeve B.F., Mahowald M.W. Delayed emergence of a parkinsonian disorder or dementia in 81% of older men initially diagnosed with idiopathic rapid eye movement sleep behavior disorder: a 16-year update on a previously reported series. Sleep Med 2013, 14:744-748.
15. Boot B.P., Boeve B.F., Roberts R.O., et al. Probable REM sleep behavior disorder increases risk for mild cognitive impairment and Parkinson's disease: a population-based study. Ann Neurol 2012, 71:49-56.
16. Claassen D.O., Josephs K.A., Ahlskog J.E., Silber M.H., Tippmann-Peikert M., Boeve B.F. REM sleep behavior disorder preceding other aspects of synucleinopathies by up to half a century. Neurology 2010, 75:494-499.
17. Howell M.J. Parasomnias: an updated review. Neurother 2012, 9(4):753-775. 10.1007/s13311-012-0143-8.
18. Postuma R.B., Gagnon J.F., Tuineaig M., Bertrand J.A., Latreille V., Desjardins C., et al. Antidepressants and REM sleep behavior disorder: isolated side effect or neurodegenerative signal?. Sleep 2013, 36(11):1579-1585.
19. Gugger J.J., Wagner M.L. Rapid eye movement sleep behavior disorder. Ann Pharmacother 2007, 41:1833-1841.
20. Aurora R.N., Zak R.S., Maganti R.K., et al. Best practice guide for the treatment of REM sleep behavior disorder (RBD). J Clin Sleep Med 2010, 6(1):85-95.
21. McCarter S.J., Boswell C.L., St Louis E.K., et al. Treatment outcomes in REM sleep behavior disorder. Sleep Med 2013, 14(3):237-242. 10.1016/j.sleep.2012.09.018.
22. Kunz D., Bes F. Melatonin effects in a patient with severe REM sleep behavior disorder: case report and theoretical considerations. Neuropsychobiology 1997, 36:211-214.
23. Boeve B.F., Silber M.H., Ferman T.J. Melatonin for treatment of REM sleep behavior disorder in neurologic disorders: results in 14 patients. Sleep Med 2003, 4(4):281-284. 10.1016/S1389-9457(03)00072-8.
24. Brzezinski A. Melatonin in humans. N Engl J Med 1997, 336:186-195.
25. Lack L., Wright H. The effect of evening bright light in delaying the circadian rhythms and lengthening the sleep of early morning awakening insomniacs. Sleep 1993, 16(5):436-443.
26. Kunz D., Schmitz S., Mahlberg R., Mohr A., Stöter C., Wolf K.J., et al. A new concept for melatonin deficit: on pineal calcification and melatonin excretion. Neuropsychopharmacology 1999, 21:756-772.
27. Zeitzer J.M., Duffy J.F., Lockley S.W., Dijk D.J., Czeisler C.A. Plasma melatonin rhythms in young and older humans during sleep, sleep deprivation, and wake. Sleep 2007, 30(11):1437-1443.
28. Iguichi H., Kato K.I., Ibayashi H. Age-dependent reduction in serum melatonin concentrations in healthy human subjects. J Clin Endocrinol Metab 1982, 55(1):27-29.
29. Dollins A.B., Zhdanova I.V., Wurtman R.J., Lynch H.J., Deng M.H. Effect of inducing nocturnal serum melatonin concentrations in daytime on sleep, mood, body temperature, and performance. Proc Natl Acad Sci U S A 1994, 91(5):1824-1828.
30. Kunz D., Mahlberg R. A two-part, double-blind, placebo-controlled trial of exogenous melatonin in REM sleep behaviour disorder. J Sleep Res 2010, 19(4):591-596. 10.1111/j.1365-2869.2010.00848.x.
31. Kunz D., Bes F. Melatonin as a therapy in REM sleep behavior disorder patients: an open-labeled pilot study on the possible influence of melatonin on REM-sleep regulation. Mov Disord 1999, 14(3):507-511.
32. Takeuchi N., Uchimura N., Hashizume Y., et al. Melatonin therapy for REM sleep behavior disorder. Psychiatry Clin Neurosci 2001, 55(3):267-269. 10.1046/j.1440-1819.2001.00854.x.
33. Lin C.M., Chiu R.N.M.S.H.Y., Guilleminault C. Melatonin and REM behavior disorder. J Sleep Disord Ther 2013, 2:118. 10.4172/2167-0277.1000118.
34. Kunz D. Melatonin in rapid eye movement sleep behavior disorder: why does it work?. Sleep Med 2013, 14(8):705-706. 10.1016/j.sleep.2013.05.004.
35. Reijnders J.S., Ehrt U., Weber W.E., Aarsland D., Leentjens A.F. A systematic review of prevalence studies of depression in Parkinson's disease. Mov Disord 2008, 23(2):183-189. quiz 313. 10.1002/mds.21803.
36. Lyketsos C.G., Lopez O., Jones B., Fitzpatrick A.L., Breitner J., DeKosky S. Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: results from the cardiovascular health study. JAMA 2002, 288(12):1475-1483.
37. Winkelman J.W., James L. Serotonergic antidepressants are associated with REM sleep without atonia. Sleep 2004, 27(2):317-321.
38. Seabra M.L., Bignotto M., Pinto L.R., Tufik S. Randomized, double-blind clinical trial, controlled with placebo, of the toxicology of chronic melatonin treatment. J Pineal Res 2000, 29(4):193-200.
39. Ellis C.M., Lemmens G., Parkes J.D. Melatonin and insomnia. J Sleep Res 1996, 5(1):61-65.
40. Kunz D., Mahlberg R., Muller C., Tilmann A., Bes F., et al. Melatonin in patients with reduced REM sleep duration: two randomized controlled trials. J Clin Endocrinol Metab 2004, 89(1):128-134.
41. Attenburrow M.E.J., Cowen P.H., Sharpley A.J. Low dose melatonin improves sleep in healthy middle-aged subjects. Psychopharmacology (Berl) 1996, 126:179-181.
42. Brooks P.L., Peever J.H. Impaired GABA and glycine transmission triggers cardinal features of rapid eye movement sleep behavior disorder in mice. J Neurosci 2011, 31(19):7111-7121.
43. Karczmar A.G., Longo V.G., Scotti de Carolis A. A pharmacological model of paradoxical sleep: the role of cholinergic and monoamine systems. Physiol Behav 1970, 5:175-182.
44. Gillin C.J., Sitaram N. Editorial: Rapid Eye Movement (REM) sleep: cholinergic mechanisms. Psychol Med 1984, 14:501-506.
45. Bowers M.B., Goodman E., Sim V.M. Some behavioral changes in man following anticholinesterase administration. Journal of Nervous and Mental Disease 1964, 138:383-389.
46. Ringman J., Simmons J. Treatment of REM sleep behavior disorder with donepezil: a report of three cases. Neurology 2000, 55:870-871.
47. de Almeida-Paula L.D., Costa-Lotufo L.V., Ferreira Z.S., Monteiro A.E.G., Isoldi M.C., Godinho R.O., et al. Melatonin modulates rat myotube-acetylcholine receptors by inhibiting calmodulin. Eur J Pharmacol 2005, 525:24-31. 10.1016/j.ejphar.2005.09.056.
48. Markus R.P., Silva C.L.M., Franco D.G., Barbosa E.M., Ferreira Z.S. Is modulation of nicotinic acetylcholine receptors by melatonin relevant for therapy with cholinergic drugs?. Pharmacol Therapeut 2010, 126:251-262. 10.1016/j.pharmthera.2010.02.009.
49. Benitez-King G. Melatonin as a cytoskeletal modulator: implications for cell physiology and disease. J Pineal Res 2006, 40:1-9.
50. Buharalioglu C.K., Akar F. The reactivity of serotonin, acetylcholine and KCL-induced contractions to relaxant agents in the rat gastric fundus. Pharmacol Res 2002, 45:325-331. 10.1006/phrs.2002.0950.
51. Velarde E., Delgado M.J., Alonso-Gomez A.L. Serotonin induced contraction in isolated intestine from a teleost fish (Carassius auratus): characterization and interactions with melatonin. Neurogastroenterol Motil 2010, 22:364-373. 10.1111/j.1365-2982.2010.01605.x.
52. Wappler F., Scholz J., von Richthofen V., Fiege M., Kochling A., Lambrecht W., et al. Attenuation of serotonin-induced contractures in skeletal muscle from malignant hyperthermia-susceptible patients with dantrolene. Acta Anaesthesiol Scand 1997, 41:1312-1318.
53. San L., Arranz B. Agomelatine: a novel mechanism of antidepressant action involving the melatonergic and the serotonergic system. Eur Psychiatry 2008, 6:396-402.
54. Bonakis A., Economou N., Papageorgiou S., Vaviakis E., Nanas S., Paparrigopoulos T. Agomelatine may improve REM sleep behavior disorder symptoms. J Clin Psychopharmacol 2012, 32:732-735.
55. Nomura T., Kawase S., Watanabe Y., Nakashima K. Use of ramelteon for the treatment of secondary REM sleep behavior disorder. Intern Med 2013, 52:2123-2126. 10.2169/internalmedicine.52.9179.
56. Fick D., Semla T., Beizer J., et al. American geriatrics society updated beers criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc 2012, 60(4):616-631. 10.1111/j.1532-5415.2012.03923.x.
57. Anderson K.N., Shneerson J.M. Drug treatment of REM sleep behavior disorder: the use of drug therapies other than clonazepam. J Clin Sleep Med 2009, 5(3):235-239.
58. St Louis E.K. Truly "rational" polytherapy: maximizing efficacy and minimizing drug interactions, drug load, and adverse effects. Curr Neuropharmacol 2009, 7(2):96-105.
59. Salzman B. Gait and balance disorders in older adults. Am Fam Physician 2010, 82(1):61-68.
60. Morris M.E., Iansek R., Matyas T.A., Summers J.J. The pathogenesis of gait hypokinesia in Parkinsons-disease. Brain 1994, 117:1169-1181. 10.1093/brain/117.5.1169.
61. Klonapin® [package insert] 2013, Genentech USA, Inc, San Francisco, CA.
62. Code of federal regulation, title 21, volume 9 [Internet]. FDA website, [Published 7.2.14. Updated 9.1.14. Accessed 10.28.14.]. http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=1308.14.
63. Schenck C.H., Montplaisir J.Y., Frauscher B., et al. Rapid eye movement sleep behavior disorder: devising controlled active treatment studies for symptomatic and neuroprotective therapy-a consensus statement from the International Rapid Eye Movement Sleep Behavior Disorder Study Group. Sleep Med 2013, 14(8):795-806. 10.1016/j.sleep.2013.02.016.